NCT04030195View on ClinicalTrials.gov

Dose-escalation Study of Safety of PBCAR20A in Subjects With r/r NHL or r/r CLL/SLL

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

March 24, 2020

Primary Completion Date

June 24, 2021

Study Completion Date

June 24, 2021

Conditions
Non-Hodgkin's Lymphoma, RelapsedChronic Lymphoid Leukemia in RelapseNon-Hodgkin's Lymphoma RefractoryChronic Lymphocytic LeukemiaLymphoma, Non-HodgkinLeukemia, Lymphocytic, ChronicB-cell Chronic Lymphocytic LeukemiaB-cell Non Hodgkin LymphomaSmall Lymphocytic Lymphoma
Interventions
GENETIC

PBCAR20A

"Single dose of Allogeneic Anti-CD20 CAR T cells will be infused, and a classic 3+3 dose escalation will be applied."

DRUG

Fludarabine

Fludarabine is used for lymphodepletion (30 mg/m\^2/day, Days -5 to -3).

DRUG

Cyclophosphamide

Cyclophosphamide is used for lymphodepletion (500 mg/m\^2/day, Days -5 to -3).

Trial Locations (5)

10032

Columbia University, New York

44195

Cleveland Clinic, Cleveland

77030

MD Anderson Cancer Center, Houston

91010

City of Hope, Duarte

94305

Stanford University, Stanford

Sponsors
All Listed Sponsors
lead

Precision BioSciences, Inc.

INDUSTRY

NCT04030195 - Dose-escalation Study of Safety of PBCAR20A in Subjects With r/r NHL or r/r CLL/SLL | Biotech Hunter | Biotech Hunter